SAN

85.39

-1.78%↓

MRK1

119.75

+2.97%↑

ARGX

788.2

+1.44%↑

PHIA

24.16

-0.86%↓

ONC.US

329.61

-1.52%↓

SAN

85.39

-1.78%↓

MRK1

119.75

+2.97%↑

ARGX

788.2

+1.44%↑

PHIA

24.16

-0.86%↓

ONC.US

329.61

-1.52%↓

SAN

85.39

-1.78%↓

MRK1

119.75

+2.97%↑

ARGX

788.2

+1.44%↑

PHIA

24.16

-0.86%↓

ONC.US

329.61

-1.52%↓

SAN

85.39

-1.78%↓

MRK1

119.75

+2.97%↑

ARGX

788.2

+1.44%↑

PHIA

24.16

-0.86%↓

ONC.US

329.61

-1.52%↓

SAN

85.39

-1.78%↓

MRK1

119.75

+2.97%↑

ARGX

788.2

+1.44%↑

PHIA

24.16

-0.86%↓

ONC.US

329.61

-1.52%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Open

1.353 -0.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.351

Max

1.391

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.009
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	5.5M 1B
Vorheriger Eröffnungskurs	1.94
Vorheriger Schlusskurs	1.353

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Dez. 2025, 17:29 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2. Dez. 2025, 16:21 UTC

Ergebnisse

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2. Dez. 2025, 16:18 UTC

Ergebnisse

Correction to Scotiabank Quarterly Earnings Buoyed Article

2. Dez. 2025, 23:53 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

2. Dez. 2025, 22:48 UTC

Ergebnisse

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2. Dez. 2025, 22:12 UTC

Market Talk

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2. Dez. 2025, 22:03 UTC

Market Talk

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2. Dez. 2025, 22:00 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Dez. 2025, 22:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Dez. 2025, 22:00 UTC

Market Talk

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2. Dez. 2025, 21:56 UTC

Ergebnisse

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. Dez. 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Dez. 2025, 21:44 UTC

Ergebnisse

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. Dez. 2025, 21:38 UTC

Market Talk

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2. Dez. 2025, 21:19 UTC

Ergebnisse

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2. Dez. 2025, 20:06 UTC

Market Talk

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2. Dez. 2025, 19:55 UTC

Market Talk

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2. Dez. 2025, 19:53 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

2. Dez. 2025, 19:53 UTC

Market Talk

Ergebnisse

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2. Dez. 2025, 19:24 UTC

Market Talk

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2. Dez. 2025, 19:06 UTC

Market Talk

Precious Metals Step Back After Silver Sets Record -- Market Talk

2. Dez. 2025, 18:27 UTC

Akquisitionen, Fusionen, Übernahmen

Kraken to Acquire Backed Finance AG

2. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Dez. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Dez. 2025, 15:17 UTC

Market Talk

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2. Dez. 2025, 14:47 UTC

Market Talk

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2. Dez. 2025, 14:38 UTC

Market Talk

Silver Steps Back From Record Levels -- Market Talk

2. Dez. 2025, 14:31 UTC

Market Talk

Ergebnisse

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.